The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

  • Funded by National Institutes of Health (NIH)
  • Total publications:1 publications

Grant number: 3U2CCA233238-01S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2018
    2023
  • Known Financial Commitments (USD)

    $159,890
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Avrum E Spira
  • Research Location

    United States of America
  • Lead Research Institution

    Boston University Medical Campus
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In this proposal, that enhances ongoing Lung PCA studies, we propose aims to examine the protein localization, cell type specific expression, and biological pathways up-regulated with key SARS-CoV-2 viral entry genes across the various stages of lung cancer development. We will compare these results with protein expression of key SARS-CoV-2 viral entry genes as well as immune, epithelial, and endothelial cell proteins in lung tissue from patients that died from COVID-19, and from lung tissue sampled pre- and post-COVID-19 disease. Spatially characterizing the epithelium and stromal microenvironment and expression of key SARS-CoV-2 entry genes during the development of lung cancer in the central airway and the alveoli may identify potential ways to improve clinical management of this high-risk patient population and improve COVID-19 outcomes

Publicationslinked via Europe PMC

Smoking modulates different secretory subpopulations expressing SARS-CoV-2 entry genes in the nasal and bronchial airways.